Home › Multipel myeloom › District of Columbia › Washington
Multipel myeloom klinische studies in Washington, DC
22 studies voor Multipel myeloom zoeken deelnemers op locaties in en rond Washington (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RekruterenFase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mijl verwijderd
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruterenFase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RekruterenObservatieonderzoek
- National Institutes of Health Clinical Center, Bethesda · 7 mijl verwijderd
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RekruterenFase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mijl verwijderd
Tissue Collection for Studies of Lymph Cancer
RekruterenObservatieonderzoek
- National Institutes of Health Clinical Center, Bethesda · 7 mijl verwijderd
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RekruterenFase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mijl verwijderd
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruterenFase 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mijl verwijderd
18F-Fluciclovine PET/CT in Multiple Myeloma
RekruterenFase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mijl verwijderd
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruterenFase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mijl verwijderd
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
RekruterenFase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
RekruterenObservatieonderzoek
- National Institutes of Health Clinical Center, Bethesda · 7 mijl verwijderd
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekruterenFase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RekruterenFase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
RekruterenFase 2
- GSK Investigational Site, Bethesda · 7 mijl verwijderd
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekruterenFase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Rekruteren
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 mijl verwijderd
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RekruterenFase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mijl verwijderd
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruterenFase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RekruterenFase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruterenFase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Multipel myeloom studies in andere steden
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA42 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Edison, NJ22 studies
Andere studies in Washington
- Kanker (alle vormen)58 studies
- Niet-kleincellige longkanker55 studies
- Borstkanker46 studies
- Metastatische kanker43 studies
- Longkanker41 studies
- Prostaatkanker38 studies
- Obesitas33 studies
- Colorectale kanker29 studies
- Cardiovasculaire ziekte28 studies
- Blasenkanker26 studies
- Acute myeloïde leukemie24 studies
- Eierstokkanker23 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.